Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03097315 · ClinicalTrials.gov registry record · Phase 3
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
A Phase 3 study, sponsored by Clearside Biomedical.
- Completed
- Registry status
- Phase 3
- Development phase
- 38
- Enrollment target
NCT03097315 is a Phase 3 study that has completed, run by Clearside Biomedical. The registered enrollment target is 38 participants.
The verdict
NCT03097315, a Phase 3 study, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 38 participants
- Enrollment target
Study Summary
This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
Interventions
- DRUG 4 mg CLS-TA Suprachoriodal Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2018-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03097315
The ClinicalTrials.gov registry entry for NCT03097315 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 4 mg CLS-TA Suprachoriodal Injection is the first listed.
NCT03097315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03097315 about?
NCT03097315 is a clinical study titled "Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis". This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
What is the current status of trial NCT03097315?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 38 participants. The study started on 2017-04-04. Estimated completion is 2018-01-24.
What interventions are being tested in trial NCT03097315?
The interventions under investigation include: 4 mg CLS-TA Suprachoriodal Injection (DRUG).
Who is sponsoring clinical trial NCT03097315?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.